Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart-Safe chemo? new study tests vasodilators to prevent chest pain in cancer patients

NCT ID NCT07456852

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase I/II trial tests whether vasodilator drugs (isosorbide mononitrate or diltiazem) can prevent blood vessel damage caused by fluoropyrimidine chemotherapy in 60 patients with gastrointestinal cancer. Researchers will monitor blood vessel reactivity using a non-invasive device called EndoPAT. The goal is to reduce chest pain and heart risks during treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
isosorbide mononitrate, diltiazem, or placebo
What this could lead to
If it works, this could point toward a way to prevent chemotherapy-related blood vessel damage and chest pain, making cancer treatment safer.
What could go wrong
This is an early-phase pilot study with only 60 participants, so results may not apply broadly. The vasodilator drugs themselves can cause side effects like low blood pressure or dizziness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT DIGESTIVE SYSTEM NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT DIGESTIVE SYSTEM NEOPLASM

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.